

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the management of gastric... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-1365/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-1365" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the management of gastric adenocarcinoma patients" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the management of gastric adenocarcinoma patients.">
            <meta name="og:description" content="Read the latest article version by Kazuto Harada, Anthony Lopez, Namita Shanbhag, Brian Badgwell, Hideo Baba, Jaffer Ajani, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="16487">
            <meta name="article-id" content="15133">
            <meta name="dc.title" content="Recent advances in the management of gastric adenocarcinoma patients">
            <meta name="dc.description" content="Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide advantage. For locally advanced GAC (&amp;gt;cT1B), the emerging strategies have included preoperative chemotherapy, postoperative adjuvant chemotherapy, and (occasionally) postoperative chemoradiation in various regions. Several novel therapies have been assessed in clinical trials, but only trastuzumab and ramucirumab (alone and in combination with paclitaxel) have shown overall survival advantage. Pembrolizumab has been approved by the US Food and Drug Administration on the basis of response rate only for patients with microsatellite instability (MSI-H) or if PD-L1 expression is positive (&ge;1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen). Nivolumab has been approved in Japan on the basis of a randomized trial showing significant survival advantage for patients who received nivolumab compared with placebo in the third or later lines of therapy. The cure rate of patients with localized GAC in the West is only about 40% and that for metastatic cancer is very poor (only 2&ndash;3%). At this stage, much more target discovery is needed through molecular profiling. Personalized therapy of patients with GAC remains a challenge.">
            <meta name="dc.subject" content="Gastric adenocarcinoma, preoperative therapy, targeted therapy,">
            <meta name="dc.creator" content="Harada, Kazuto">
            <meta name="dc.creator" content="Lopez, Anthony">
            <meta name="dc.creator" content="Shanbhag, Namita">
            <meta name="dc.creator" content="Badgwell, Brian">
            <meta name="dc.creator" content="Baba, Hideo">
            <meta name="dc.creator" content="Ajani, Jaffer">
            <meta name="dc.date" content="2018/08/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.15133.1">
            <meta name="dc.source" content="F1000Research 2018 7:1365">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Gastric adenocarcinoma">
            <meta name="prism.keyword" content="preoperative therapy">
            <meta name="prism.keyword" content="targeted therapy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/08/30">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="1365">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.15133.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-1365">
            <meta name="citation_title" content="Recent advances in the management of gastric adenocarcinoma patients">
            <meta name="citation_abstract" content="Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide advantage. For locally advanced GAC (&amp;gt;cT1B), the emerging strategies have included preoperative chemotherapy, postoperative adjuvant chemotherapy, and (occasionally) postoperative chemoradiation in various regions. Several novel therapies have been assessed in clinical trials, but only trastuzumab and ramucirumab (alone and in combination with paclitaxel) have shown overall survival advantage. Pembrolizumab has been approved by the US Food and Drug Administration on the basis of response rate only for patients with microsatellite instability (MSI-H) or if PD-L1 expression is positive (&ge;1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen). Nivolumab has been approved in Japan on the basis of a randomized trial showing significant survival advantage for patients who received nivolumab compared with placebo in the third or later lines of therapy. The cure rate of patients with localized GAC in the West is only about 40% and that for metastatic cancer is very poor (only 2&ndash;3%). At this stage, much more target discovery is needed through molecular profiling. Personalized therapy of patients with GAC remains a challenge.">
            <meta name="citation_description" content="Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide advantage. For locally advanced GAC (&amp;gt;cT1B), the emerging strategies have included preoperative chemotherapy, postoperative adjuvant chemotherapy, and (occasionally) postoperative chemoradiation in various regions. Several novel therapies have been assessed in clinical trials, but only trastuzumab and ramucirumab (alone and in combination with paclitaxel) have shown overall survival advantage. Pembrolizumab has been approved by the US Food and Drug Administration on the basis of response rate only for patients with microsatellite instability (MSI-H) or if PD-L1 expression is positive (&ge;1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen). Nivolumab has been approved in Japan on the basis of a randomized trial showing significant survival advantage for patients who received nivolumab compared with placebo in the third or later lines of therapy. The cure rate of patients with localized GAC in the West is only about 40% and that for metastatic cancer is very poor (only 2&ndash;3%). At this stage, much more target discovery is needed through molecular profiling. Personalized therapy of patients with GAC remains a challenge.">
            <meta name="citation_keywords" content="Gastric adenocarcinoma, preoperative therapy, targeted therapy,">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Kazuto Harada">
            <meta name="citation_author_institution" content="Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA">
            <meta name="citation_author_institution" content="Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan">
            <meta name="citation_author" content="Anthony Lopez">
            <meta name="citation_author_institution" content="Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA">
            <meta name="citation_author_institution" content="Department of Gastroenterology and Hepatology and Inserm U954, Nancy University Hospital, Lorraine University, 5 all&eacute;e du Morvan, 54511 Vandoeuvre-l&egrave;s-Nancy, France">
            <meta name="citation_author" content="Namita Shanbhag">
            <meta name="citation_author_institution" content="Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA">
            <meta name="citation_author" content="Brian Badgwell">
            <meta name="citation_author_institution" content="Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA">
            <meta name="citation_author" content="Hideo Baba">
            <meta name="citation_author_institution" content="Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan">
            <meta name="citation_author" content="Jaffer Ajani">
            <meta name="citation_author_institution" content="Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA">
            <meta name="citation_publication_date" content="2018/08/30">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="1365">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.15133.1">
            <meta name="citation_firstpage" content="1365">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-1365/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-1365.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=16487 /> <input type=hidden id=articleId name=articleId value=15133 /> <input type=hidden id=xmlUrl value="/articles/7-1365/v1/xml"/> <input type=hidden id=xmlFileName value="-7-1365-v1.xml"> <input type=hidden id=article_uuid value=7b18fc0c-d803-441a-a98b-232f0bb38fdc /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the management of gastric adenocarcinoma patients"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.15133.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.15133.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-1365"
  },
  "headline": "Recent advances in the management of gastric adenocarcinoma patients",
  "datePublished": "2018-08-30T16:54:07",
  "dateModified": "2018-08-30T16:54:07",
  "author": [
    {
      "@type": "Person",
      "name": "Kazuto Harada"
    },    {
      "@type": "Person",
      "name": "Anthony Lopez"
    },    {
      "@type": "Person",
      "name": "Namita Shanbhag"
    },    {
      "@type": "Person",
      "name": "Brian Badgwell"
    },    {
      "@type": "Person",
      "name": "Hideo Baba"
    },    {
      "@type": "Person",
      "name": "Jaffer Ajani"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide advantage. For locally advanced GAC (&amp;gt;cT1B), the emerging strategies have included preoperative chemotherapy, postoperative adjuvant chemotherapy, and (occasionally) postoperative chemoradiation in various regions. Several novel therapies have been assessed in clinical trials, but only trastuzumab and ramucirumab (alone and in combination with paclitaxel) have shown overall survival advantage. Pembrolizumab has been approved by the US Food and Drug Administration on the basis of response rate only for patients with microsatellite instability (MSI-H) or if PD-L1 expression is positive (&ge;1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen). Nivolumab has been approved in Japan on the basis of a randomized trial showing significant survival advantage for patients who received nivolumab compared with placebo in the third or later lines of therapy. The cure rate of patients with localized GAC in the West is only about 40% and that for metastatic cancer is very poor (only 2&ndash;3%). At this stage, much more target discovery is needed through molecular profiling. Personalized therapy of patients with GAC remains a challenge."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-1365",
            "name": "Recent advances in the management of gastric adenocarcinoma patients"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the management of gastric adenocarcinoma patients </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=16487 data-id=15133 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15133.1" data-recommended="" data-doi="10.12688/f1000research.15133.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-1365/v1/pdf?article_uuid=7b18fc0c-d803-441a-a98b-232f0bb38fdc" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-15133-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-15133-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-15133-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Harada K, Lopez A, Shanbhag N <em>et al.</em> Recent advances in the management of gastric adenocarcinoma patients [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1365 (<a class=new-orange href="https://doi.org/10.12688/f1000research.15133.1" target=_blank>https://doi.org/10.12688/f1000research.15133.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-15133-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=15133 id=track-article-signin-15133 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15133?target=/articles/7-1365">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16487 /> <input name=articleId type=hidden value=15133 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the management of gastric adenocarcinoma patients</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Kazuto Harada<a href="https://orcid.org/0000-0001-5818-7072" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5818-7072</div><sup>1,2</sup>,&nbsp;</span><span class="">Anthony Lopez<sup>1,3</sup>,&nbsp;</span><span class="">Namita Shanbhag<sup>1</sup>,&nbsp;</span><span class="">Brian Badgwell<sup>4</sup>,&nbsp;</span><span class="">Hideo Baba<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:jajani@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jaffer Ajani</span></a><sup>1</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Kazuto Harada<a href="http://orcid.org/0000-0001-5818-7072" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-5818-7072</div><sup>1,2</sup>,&nbsp;</span><span class="">Anthony Lopez<sup>1,3</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Namita Shanbhag<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Brian Badgwell<sup>4</sup>,&nbsp;</span><span class="">Hideo Baba<sup>2</sup>,&nbsp;</span><span class=""><a href="mailto:jajani@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jaffer Ajani</span></a><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Aug 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.15133.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA<br/> <sup>2</sup> Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan<br/> <sup>3</sup> Department of Gastroenterology and Hepatology and Inserm U954, Nancy University Hospital, Lorraine University, 5 all&eacute;e du Morvan, 54511 Vandoeuvre-l&egrave;s-Nancy, France<br/> <sup>4</sup> Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA<br/> <p> <div class=margin-bottom> Kazuto Harada <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Anthony Lopez <br/> <span>Roles: </span> Conceptualization, Data Curation, Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Namita Shanbhag <br/> <span>Roles: </span> Conceptualization </div> <div class=margin-bottom> Brian Badgwell <br/> <span>Roles: </span> Conceptualization </div> <div class=margin-bottom> Hideo Baba <br/> <span>Roles: </span> Conceptualization, Supervision </div> <div class=margin-bottom> Jaffer Ajani <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=38153-37409></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=22146-37410></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Gastric adenocarcinoma (GAC) is one of the most aggressive malignancies and has a dismal prognosis. Therefore, multimodality therapies to include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy are needed to provide advantage. For locally advanced GAC (&gt;cT1B), the emerging strategies have included preoperative chemotherapy, postoperative adjuvant chemotherapy, and (occasionally) postoperative chemoradiation in various regions. Several novel therapies have been assessed in clinical trials, but only trastuzumab and ramucirumab (alone and in combination with paclitaxel) have shown overall survival advantage. Pembrolizumab has been approved by the US Food and Drug Administration on the basis of response rate only for patients with microsatellite instability (MSI-H) or if PD-L1 expression is positive (≥1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen). Nivolumab has been approved in Japan on the basis of a randomized trial showing significant survival advantage for patients who received nivolumab compared with placebo in the third or later lines of therapy. The cure rate of patients with localized GAC in the West is only about 40% and that for metastatic cancer is very poor (only 2–3%). At this stage, much more target discovery is needed through molecular profiling. Personalized therapy of patients with GAC remains a challenge. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Gastric adenocarcinoma, preoperative therapy, targeted therapy, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Jaffer Ajani (<a href="mailto:jajani@mdanderson.org">jajani@mdanderson.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Jaffer Ajani </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This research was supported by generous grants from the Caporella, Dallas, Sultan, Park, Smith, Frazier, Oaks, Vanstekelenberg, Planjery, and Cantu families as well as from the Schecter Private Foundation, Rivercreek Foundation, Kevin Fund, Myer Fund, Dio Fund, Milrod Fund, and the University of Texas M.D. Anderson Cancer Center (Houston, TX, USA) multidisciplinary grant program. This research was also supported in part by the National Cancer Institute and Department of Defense awards CA138671, CA172741, CA129926, and CA150334 (JAA) and by a grant from the Japan Society for the Promotion of Science Overseas Research Fellowships and Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (KH). <br/> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Harada K <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Harada K, Lopez A, Shanbhag N <em>et al.</em> Recent advances in the management of gastric adenocarcinoma patients [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1365 (<a href="https://doi.org/10.12688/f1000research.15133.1" target=_blank>https://doi.org/10.12688/f1000research.15133.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Aug 2018, <b>7</b>(F1000 Faculty Rev):1365 (<a href="https://doi.org/10.12688/f1000research.15133.1" target=_blank>https://doi.org/10.12688/f1000research.15133.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Aug 2018, <b>7</b>(F1000 Faculty Rev):1365 (<a href="https://doi.org/10.12688/f1000research.15133.1" target=_blank>https://doi.org/10.12688/f1000research.15133.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d15958e246>Introduction</h2><p class="" id=d15958e249>Gastric adenocarcinoma (GAC) is considered the fifth most common cancer in the world (1,313,000 cases) and the third leading cause of cancer death globally (819,000 deaths)<sup><a href="#ref-1">1</a></sup>. Its incidence varies according to the region: high incidence in East Asia and South America but low incidence in the West<sup><a href="#ref-1">1</a></sup>. In East Asia, especially Japan and Korea, the incidence of distal GAC is high, whereas proximal GAC has a higher incidence in the West<sup><a href="#ref-2">2</a></sup>. GAC located in the cardia or the gastroesophageal junction (or both) has dramatically increased in incidence in the USA<sup><a href="#ref-3">3</a></sup>. This trend of proximal migration of GAC is also being observed in Asia and South America along with Europe. Based on American Joint Committee on Cancer 8 (AJCC 8), gastroesophageal junction adenocarcinoma that has its epicenter in the proximal 2 to 5 cm of the stomach (Siewert type III) should be staged and treated as GAC. For locally advanced GAC, various strategies have been developed in different regions of the world and these have evolved on the basis of practice preferences and types of clinical trials performed. For example, preoperative chemotherapy is favored in the European Union and the USA, whereas postoperative adjuvant chemotherapy is preferred in Asia. Postoperative chemoradiation has a diminishing role while the quality of surgery appears to be improving. Adjunctive therapy (preoperative or postoperative) seems to increase the cure rate by about 10%. Multidisciplinary evaluation is essential to improve patient outcomes and for the initial treatment decision process.</p><p class="" id=d15958e268>For metastatic GAC, the standard-of-care therapies have a limited impact on patient outcome. The median survival of patients with advanced GAC is less than 12 months. Only a limited number of therapies are approved, and many of these therapies are done empirically. Here, we summarize recent advances in the management of GAC.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15958e274>Molecular features of gastric adenocarcinoma</h2><p class="" id=d15958e277>Two groups—The Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG)—have reported multiplatform sequencing of primary GACs (TCGA analysis being more comprehensive than ACRG) and, out of these efforts, four genotypes of GAC have emerged<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. TCGA data were more comprehensive and basically GACs have been divided into those with microsatellite instability (MSI), chromosomal instability (CIN), genome stability (GS), and Epstein–Barr virus (EBV) association<sup><a href="#ref-5">5</a></sup>. The MSI cohort represented about 22% and was more frequent in the distal GAC than the proximal GAC. In contrast, CIN is more frequent in the proximal GAC. Compared with other gastrointestinal adenocarcinomas, CIN in GAC tends to have focal region alterations<sup><a href="#ref-6">6</a></sup>. GS and EBV had frequencies of 20% and 9%, respectively.</p><p class="" id=d15958e295>Certain molecular subtypes are associated with shorter survival; for example, GS and CIN have poor prognosis<sup><a href="#ref-4">4</a>,<a href="#ref-7">7</a></sup>. The GS subtype of GAC is enriched in diffuse-type histology and is molecularly characterized by less mutation and overexpression of epithelial–mesenchymal transition-related genes<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. On the other hand, the CIN subtype of GAC is enriched in intestinal histology and is molecularly characterized by <i>TP53</i> mutation and <i>RTK-RAS</i> activation/amplifications<sup><a href="#ref-4">4</a>,<a href="#ref-5">5</a></sup>. MSI subtyped GAC harbors numerous somatic mutations, leading to a large number of neoantigens that can activate T cells<sup><a href="#ref-8">8</a></sup>. Thus, GACs with MSI respond well to immune checkpoint blockade<sup><a href="#ref-9">9</a></sup>. However, the frequency of MSI-H and EBV-related GACs in the metastatic setting is low (&lt;3%).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15958e337>Resectable gastric adenocarcinoma</h2><div class=section><a name=d15958e340 class=n-a></a><h3 class=section-title>Primary resection</h3><p class="" id=d15958e345>GAC with clinical T1N0 can be treated by either endoscopic therapy or surgery without any adjunctive therapy, while advanced localized GAC should undergo either preoperative therapy or surgery first followed by adjuvant chemotherapy. Adequate lymphadenectomy (D2 dissection) is desired with gastrectomy<sup><a href="#ref-10">10</a></sup>. If the depth of invasion suggests eusT1a, then endoscopic resection is preferred according to the Japanese guidelines<sup><a href="#ref-10">10</a></sup>. When surgery is performed first, postoperative adjuvant chemotherapy should be considered on the basis of the pathological stage or quality of surgery.</p></div><div class=section><a name=d15958e357 class=n-a></a><h3 class=section-title>Postoperative treatment</h3><p class="" id=d15958e362>Postoperative adjuvant chemotherapy is the most common strategy in East Asia. The ACTS-GC trial, a phase III trial in Japan, showed that postoperative adjuvant therapy with S-1 for 12 months improved overall survival (OS) (5-year OS 72% versus 61%, hazard rate [HR] 0.67, 95% confidence interval [CI] 0.52–0.82) and relapse-free survival (RFS) (5-year RFS 65% versus 53%, HR 0.65, 95% CI 0.54–0.79) in GAC patients with stage II/III who underwent D2 gastrectomy<sup><a href="#ref-11">11</a></sup>. The CLASSIC trial, a phase III trial performed in South Korea, China, and Taiwan, showed that adjuvant capecitabine plus oxaliplatin combination given for 6 months after D2 gastrectomy improved OS (5-year OS 78% versus 69%, HR 0.66, 95% CI 0.51–0.85) and RFS (5-year RFS 68% versus 53%, HR 0.58, 95% CI 0.47–0.72)<sup><a href="#ref-12">12</a></sup>. These trials are the basis for recommending postoperative chemotherapy after optimal surgery. More intensive regimens have no advantage for postoperative chemotherapy<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Recently, the JACCRO GC-07 trial suggests that S-1 plus docetaxel has significant advantage over S-1 alone and it has become the standard of care<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d15958e384>Efficacy of postoperative chemoradiation was shown in the INT-0116 trial; compared with the surgery-alone group, the postoperative chemoradiotherapy group had longer OS (median OS 27 versus 36 months, HR 1.35, 95% CI 1.09–1.66) and RFS (median RFS 19 versus 30 months, HR 1.52, 95% CI 1.23–1.86)<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. However, the quality of surgery was suboptimum in patients enrolled in this trial; D0, D1, and D2 lymph node dissection rates were 54%, 36%, and 10%, respectively. Importantly, the ARTIST and CRITICS trials demonstrated the lack of efficacy of postoperative chemoradiation after D2 or D1+ nodal dissection<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>. Therefore, postoperative chemoradiation is not useful if optimal or near-optimal surgery is performed.</p></div><div class=section><a name=d15958e402 class=n-a></a><h3 class=section-title>Preoperative treatment</h3><p class="" id=d15958e407>The MAGIC trial provided evidence that perioperative chemotherapy (three preoperative and three postoperative cycles of epirubicin, cisplatin, and fluorouracil [ECF]) for resectable GAC could improve cure rates (5-year OS 23% versus 36%, HR 0.75, 95% CI 0.60–0.93)<sup><a href="#ref-20">20</a></sup>. However, a follow-up analysis of the MAGIC results has not yet been presented. The results overall were suboptimal. Moreover, epirubicin is not necessary<sup><a href="#ref-21">21</a></sup>. The FNCLCC/FFCD trial showed that surgery plus preoperative cisplatin and fluorouracil (FP) improved OS compared with surgery alone (5-year OS 24% versus 38%, HR 0.69, 95% CI 0.50–0.95)<sup><a href="#ref-22">22</a></sup>. Recently, the MRC-OEO5 trial compared two cycles of FP and four cycles of ECF as perioperative chemotherapy and showed that the two regimens had similar OS (3-year rate 42% versus 39%, HR 0.92, 95% CI 0.79–1.08)<sup><a href="#ref-23">23</a></sup>. These results suggest that the addition of epirubicin and longer duration of chemotherapy do not provide any advantage.</p><p class="" id=d15958e426>The FLOT4 trial compared perioperative (predominantly preoperative) chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) and ECF/ECX<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. A total of 716 patients were randomly assigned to the ECF/ECX group (n = 360) or the FLOT group (n = 356). FLOT improved median RFS (30 versus 18 months, HR 0.75, <i>p</i> = 0.001) and median OS (50 versus 35 months, HR 0.77, <i>p</i> = 0.012) compared with ECF/ECX. A total of 50% of patients in the FLOT group completed the planned postoperative treatments, while 37% of patients in ECF/ECX completed them. Perioperative complications were similar across the two groups and unacceptably high<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. Grade 3–4 diarrhea, infections, sensory disorder, and neutropenia were more frequent in the FLOT group, while vomiting, nausea, thromboembolism, and anemia were more frequent in the ECF/ECX group. FLOT should not be recommended to every patient. FLOT might be more suitable for only very fit patients with GAC rather than patients with esophageal or gastroesophageal junction adenocarcinoma where chemoradiation followed by surgery is the preferred strategy. FLOT resulted in 90-day mortality of 5% and grade 3–4 diarrhea (10%) and infections (18%). The follow-up in this trial is also short, and it is likely that, with further follow-up, the differences between the two regimens will narrow. If the 5-year OS rate of FLOT is about 40%, then it would not be a major advance.</p><p class="" id=d15958e449>The efficacy of targeted therapy for perioperative treatment was assessed. The ST03 trial evaluated whether adding bevacizumab to perioperative chemotherapy could improve survival<sup><a href="#ref-26">26</a></sup>. A total of 1,063 patients were randomly assigned to receive chemotherapy alone (n = 533) or chemotherapy plus bevacizumab (n = 530), and prognosis was similar in the two groups (3-year OS 50.3% versus 48.1%, HR 1.08, 95% CI 0.91–1.29, <i>p</i> = 0.36)<sup><a href="#ref-26">26</a></sup>. Moreover, anastomotic leak was more frequent in the chemotherapy-plus-bevacizumab group<sup><a href="#ref-26">26</a></sup>. To date, there is no place for targeted therapy in the preoperative setting. PETRARCA/FLOT6 (ClinicalTrials.gov Identifier: NCT02581462) is evaluating the efficacy of adding herceptin/pertuzumab to perioperative chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive GAC. RAMSES/FLOT7 (ClinicalTrials.gov Identifier: NCT02661971) is evaluating the efficacy of adding ramucirumab (VEGFR2 monoclonal antibody) for HER2-negative GAC.</p><p class="" id=d15958e467>For esophageal or gastroesophageal junction adenocarcinoma, the CROSS trial documented benefit of preoperative chemoradiation<sup><a href="#ref-27">27</a></sup>. For GAC, preoperative chemoradiation is an attractive but non-standard option. Several trials have evaluated the efficacy of preoperative chemoradiation<sup><a href="#ref-28">28</a>–<a href="#ref-31">31</a></sup>, and a retrospective study at the M.D. Anderson Cancer Center showed excellent prognosis of GAC patients who had preoperative chemoradiation<sup><a href="#ref-32">32</a></sup>. To date, phase III trials assessing the value of preoperative chemoradiation in GAC are ongoing. The TOPGEAR trial is assessing the efficacy of adding preoperative radiation to the MAGIC trial regimen<sup><a href="#ref-33">33</a></sup>. The CRITICS-II trial is comparing three arms: preoperative chemotherapy followed by surgery, preoperative chemotherapy and subsequent chemoradiation followed by surgery, and preoperative chemoradiation followed by surgery (ClinicalTrials.gov Identifier: NCT02931890). Result of these trials are expected.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15958e493>Standard treatment for metastatic patients</h2><div class=section><a name=d15958e496 class=n-a></a><h3 class=section-title>Standard first-line therapy</h3><p class="" id=d15958e501>The recommended first-line therapy for patients with HER2-negative GAC is a two-drug combination of oxaliplatin (preferred) or cisplatin plus 5-FU or capecitabine. For HER2-positive GAC, the ToGA study showed that trastuzumab should be added to the first-line cytotoxic therapy<sup><a href="#ref-34">34</a></sup>. Irinotecan or taxane should be considered when platinum-based chemotherapy cannot be tolerated in the first-line setting<sup><a href="#ref-35">35</a>–<a href="#ref-37">37</a></sup>. DCF (docetaxel, cisplatin, and 5-FU) provides marginal OS advantage but its toxicity is significant<sup><a href="#ref-38">38</a>,<a href="#ref-39">39</a></sup>. Therefore, a modified regimen has been evaluated<sup><a href="#ref-40">40</a>–<a href="#ref-43">43</a></sup>. Modified DCF is still one of the options in selected cases, but the routine use of a taxane in the first-line setting should be avoided. Also, ECF is not recommended for metastatic GAC<sup><a href="#ref-44">44</a></sup>.</p></div><div class=section><a name=d15958e534 class=n-a></a><h3 class=section-title>Standard second-/third-line therapy</h3><p class="" id=d15958e539>In the second-line therapy setting, ramucirumab is the only molecular-targeted drug with a confirmed but marginal survival benefit (as a single agent) in a global phase III trial. The RAINBOW study showed that OS as a result of ramucirumab plus paclitaxel was significantly longer than in the placebo-plus-paclitaxel group (median OS 9.6 versus 7.4 months) and thus this regimen is the preferred choice for second-line therapy<sup><a href="#ref-45">45</a></sup>. Ramucirumab monotherapy is not recommended<sup><a href="#ref-46">46</a>,<a href="#ref-47">47</a></sup>. Docetaxel, irinotecan, and paclitaxel have significantly prolonged OS compared with best supportive care (BSC)<sup><a href="#ref-48">48</a>–<a href="#ref-50">50</a></sup>. However, the data on these molecules are based on a few small trials.</p></div><div class=section><a name=d15958e561 class=n-a></a><h3 class=section-title>Treatment for peritoneal metastatic gastric adenocarcinoma</h3><p class="" id=d15958e566>There is no established therapy for peritoneal carcinomatosis, which is a common site of metastases in patients with advanced GAC. Systemic chemotherapy or BSC is often recommended<sup><a href="#ref-28">28</a></sup>. Recently, intraperitoneal chemotherapy or hyperthermic intraperitoneal chemoperfusion (HIPEC) has been assessed as a potential therapy for peritoneal metastases. PHOENIX-GC, a Japanese phase III trial, compared S-1 in combination with intravenous/intraperitoneal paclitaxel and S-1 in combination with intravenous cisplatin (standard therapy in Japan)<sup><a href="#ref-51">51</a></sup>. Primary results showed that there was no significant difference between the two groups (median OS 17.7 and 15.2 months), suggesting lack of superiority of the intraperitoneal chemotherapy<sup><a href="#ref-51">51</a></sup>. A subgroup appeared to benefit, but this would only be hypothesis generating<sup><a href="#ref-52">52</a>,<a href="#ref-53">53</a></sup>. Also, perioperative intraperitoneal chemotherapy is being assessed<sup><a href="#ref-54">54</a>,<a href="#ref-55">55</a></sup>. The CY-PHOENIX trial showed that intraperitoneal chemotherapy for CY-positive patients (no other site of metastasis) resulted in conversion to CY-negative in 36 patients (94.7%) and 84.2% of the 1-year OS rate<sup><a href="#ref-55">55</a></sup>. Neoadjuvant laparoscopic HIPEC (mitomycin C 30 mg and cisplatin 200 mg) was assessed in a phase II study, which showed that seven patients (37%) had negative peritoneal cytology after HIPEC<sup><a href="#ref-56">56</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15958e608>Molecularly targeted drug for metastatic gastric adenocarcinoma</h2><div class=section><a name=d15958e611 class=n-a></a><h3 class=section-title>HER2</h3><p class="" id=d15958e616>HER2 is the only molecularly targeted drug accepted in first-line therapy. The ToGA study showed that adding trastuzumab in chemotherapy for patients with HER2-positive GAC resulted in longer median OS (13.8 versus 11.1 months, HR 0.74, 95% CI 0.60–0.91)<sup><a href="#ref-34">34</a></sup>. However, the subsequent analysis of the ToGA study showed that all of these differences have decreased by 40%. HER2 status should be tested according to guidance in all candidates for HER2-targeted therapy<sup><a href="#ref-57">57</a></sup>. The randomized phase III GATSBY trial compared T-DM1, conjugated with trastuzumab and emtansine, and taxane in patients with HER2-positive GAC in a second-line setting<sup><a href="#ref-58">58</a></sup>. However, T-DM1 failed to show benefit in OS (median OS 7.9 versus 8.6 months, HR 1.15, 95% CI 0.87–1.51)<sup><a href="#ref-58">58</a></sup>.</p><p class="" id=d15958e635>TRIO-013/LOGiC, a randomized phase III trial, assessed lapatinib, a dual inhibitor of HER2 and epidermal growth factor receptor (EGFR)<sup><a href="#ref-59">59</a></sup>. However, the addition of lapatinib to chemotherapy did not show benefit in OS for patients with HER2-positive GAC in the first-line setting (median OS 12.2 versus 10.5 months, HR 0.91, 95% CI 0.73–1.12)<sup><a href="#ref-59">59</a></sup>. TyTAN, a randomized phase III study, also showed that lapatinib was not effective for patients with HER2-positive GAC in the second-line setting (median OS 11.0 versus 8.9 months, HR 0.84, 95% CI 0.64–1.11)<sup><a href="#ref-60">60</a></sup>.</p></div><div class=section><a name=d15958e651 class=n-a></a><h3 class=section-title>EGFR</h3><p class="" id=d15958e656>EGFR-targeted therapies showed no benefit in any trials for GAC. Two trials—the EXPAND trial and the REAL3 study—failed to show a benefit from the addition of EGFR inhibitor to first-line chemotherapy<sup><a href="#ref-61">61</a>,<a href="#ref-62">62</a></sup>. To date, EGFR inhibitor is evaluated in selected patients who have EGFR overexpression with immunohistochemistry (IHC) 2+ or 3+ (ClinicalTrials.gov Identifier: NCT01813253).</p></div><div class=section><a name=d15958e667 class=n-a></a><h3 class=section-title>VEGFR</h3><p class="" id=d15958e672>Ramucirumab is marginally effective for second-line therapy based on REGARD and performs somewhat better, as shown in the RAINBOW study<sup><a href="#ref-45">45</a>,<a href="#ref-46">46</a></sup>. The RAINFALL trial assessed whether adding ramucirumab to first-line standard chemotherapy could be effective<sup><a href="#ref-63">63</a></sup>. A total of 645 patients were randomly assigned to two groups—ramucirumab plus chemotherapy (n = 326) or placebo plus chemotherapy (n = 319)—and adding ramucirumab marginally prolonged progression-free survival (PFS) (median PFS 5.7 versus 5.4 months, HR 0.75, 95% CI 0.61–0.94) but not OS (median OS 11.2 versus 10.7 months, HR 0.96, 95% CI 0.80–1.16)<sup><a href="#ref-63">63</a></sup>. These results strongly suggest that ramucirumab should not be used as first-line therapy. Bevacizumab, in the first-line setting, was found to have no efficacy when added to chemotherapy in the AVAGAST study or perioperative chemotherapy in the STO3 study<sup><a href="#ref-26">26</a>,<a href="#ref-64">64</a></sup>.</p></div><div class=section><a name=d15958e698 class=n-a></a><h3 class=section-title>MET</h3><p class="" id=d15958e703>The phase III RILOMET-1 trial compared ECX with and without MET-positive gastroesophageal adenocarcinoma, but this trial was stopped early because of a higher number of deaths in the rilotumumab group; the median OS was 8.8 months in the rilotumumab group (n = 304) compared with 10.7 months in the placebo group (n = 304)<sup><a href="#ref-65">65</a></sup>. The MET gastric trial assessed adding onartuzumab to FOLFOX in HER2-negative GAC but did not significantly benefit OS (median OS 11.0 versus 11.3 months, HR 0.82, 95% CI 0.59–1.15)<sup><a href="#ref-66">66</a></sup>. These results suggest that MET inhibitors are not particularly efficacious in most patients with MET-positive GAC.</p></div><div class=section><a name=d15958e716 class=n-a></a><h3 class=section-title>mTOR</h3><p class="" id=d15958e721>The GRANITE-1 study compared everolimus, an inhibitor of mammalian target of rapamycin (mTOR), and placebo in patients with GAC previously treated with standard care<sup><a href="#ref-67">67</a></sup>. Unfortunately, everolimus showed no benefit for OS (median OS 5.9 versus 4.3 months, HR 0.90, 95% CI 0.75–1.08)<sup><a href="#ref-67">67</a></sup>. The PADPAC study assessed adding everolimus to paclitaxel in the second-line setting but did not show significant benefit; the median OS was 6.1 months in the everolimus group (n = 150) compared with 5.1 months in the placebo group (n = 150)<sup><a href="#ref-68">68</a></sup>.</p></div><div class=section><a name=d15958e737 class=n-a></a><h3 class=section-title>FGFR2</h3><p class="" id=d15958e742>Fibroblast growth factor receptor (FGFR) inhibitor failed to show a benefit in a phase II trial, the SHINE study<sup><a href="#ref-69">69</a></sup>. GAC patients with FGFR2 amplification were randomly assigned to an AZD4547 (an FGFR inhibitor) group (n = 41) or a paclitaxel group (n = 30) and showed similar median PFS: 1.8 months in the AZD4547 group and 3.5 months in the paclitaxel group<sup><a href="#ref-69">69</a></sup>.</p></div><div class=section><a name=d15958e754 class=n-a></a><h3 class=section-title>PARP</h3><p class="" id=d15958e759>Poly (ADP-ribose) polymerase (PARP) inhibitor is potentially useful in cancers with a deficiency in the repair of double-strand breaks<sup><a href="#ref-70">70</a></sup>. In patients with GAC, a phase II trial showed that lower/absent expression level of ATM, which has a key role in activating DNA damage response to double-strand breaks, seemed to benefit from PARP inhibitor<sup><a href="#ref-71">71</a></sup>. However, the phase III GOLD study did not show an advantage from the addition of olaparib<sup><a href="#ref-72">72</a></sup>. A total of 643 patients were assigned to the olaparib-plus-paclitaxel arm (n = 263) or the placebo-plus-paclitaxel arm (n = 262), and the median OS values in the olaparib and placebo groups were 8.8 and 6.9 months, respectively (not significant)<sup><a href="#ref-72">72</a></sup>. Even in the ATM-negative population, olaparib was not effective<sup><a href="#ref-72">72</a></sup>.</p></div><div class=section><a name=d15958e783 class=n-a></a><h3 class=section-title>Targeted therapies against stem cell pathway</h3><p class="" id=d15958e788>Cancer stem cells are often resistant to therapy that is non-specific and thus can be targeted to overcome resistance<sup><a href="#ref-73">73</a></sup>. Thus far, few clinical trials have assessed the effect of inhibiting stemness-related pathways, such as the Hedgehog and signal transducer and activator of transcription 3 (STAT3) pathway. Vismodegib, an inhibitor of Hedgehog signal by binding smoothened (SMO), was assessed in a phase II randomized study, but adding vismodegib to FOLFOX did not prolong PFS (11.5 versus 9.3 months, <i>p</i> = 0.34)<sup><a href="#ref-74">74</a></sup>. Moreover, the BRIGHTER study showed that adding napabucasin, a STAT3 inhibitor, to paclitaxel did not prolong OS<sup><a href="#ref-75">75</a></sup>. The trial did not enrich patients by expression of stem cell markers in the tumor cells. It may be that selected patients should be assessed<sup><a href="#ref-76">76</a></sup>. STAT3 inhibitors may be better suited for immune modulation as well.</p></div><div class=section><a name=d15958e811 class=n-a></a><h3 class=section-title>Other targets</h3><p class="" id=d15958e816>The isoform 2 of the tight junction molecule claudin-18 (CLDN18.2) is an important component of the tight cell junctions and overexpressed significantly in GAC<sup><a href="#ref-77">77</a></sup>. IMAB362, an inhibitor of CLDN18.2, was assessed in clinical trials. In a randomized phase II trial, IMAB362 plus epirubicin, oxaliplatin, and capecitabine (EOX) significantly prolonged PFS (median 5.7 versus 7.9 months, HR 0.5, 95% CI 0.35–0.78)<sup><a href="#ref-78">78</a></sup>. Moreover, the benefit of IMAB362 was more pronounced in the patients with CLDN18.2 high-expression (70% labeling index) GAC (PFS 6.1 versus 9.1 months, HR 0.46; OS 9.3 versus 16.6 months, HR 0.44)<sup><a href="#ref-78">78</a></sup>. A phase III trial is ongoing.</p><p class="" id=d15958e831>Matrix metalloproteinase 9 (MMP9) has a key role in extracellular matrix remodeling and angiogenesis, and its inhibition in combination with FOLFOX led to potential improvement of prognosis in a phase I study<sup><a href="#ref-79">79</a></sup>. A phase III trial assessing potential benefit of MMP9 inhibition has completed accrual (ClinicalTrials.gov Identifier: NCT02545504)<sup><a href="#ref-80">80</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15958e847>Immunotherapy</h2><p class="" id=d15958e850>Immunotherapy checkpoint therapy has dramatically improved the prognosis of patients with metastatic melanoma or non-small cell lung cancer<sup><a href="#ref-81">81</a>,<a href="#ref-82">82</a></sup>, and the concept/approach has been adopted in many tumor types, including gastrointestinal malignancies. Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed death protein 1 (PD-1) and its ligand (PD-L1) are the key proteins that have the capacity to inhibit the responses of T cells that can be tumor promoting. A few phase III trials assessing the efficacy of immune checkpoint inhibitors in gastrointestinal malignancies have been conducted in patients with advanced gastric or gastroesophageal junction cancer<sup><a href="#ref-83">83</a></sup>. After two or more prior therapy failures, 493 Asian patients were randomly assigned to receive nivolumab, a PD-1 antibody, at 3 mg/kg (n = 330) or placebo (n = 163) every 2 weeks. The median OS was 5.3 months in the nivolumab group versus 4.1 months in the control group (<i>p</i> &lt;0.0001). The median PFS was also slightly longer with nivolumab compared with placebo (HR 0.60, 95% CI 0.49–0.75). The safety profile was excellent; the grade 3 or 4 treatment-related adverse event rate was 10% in the nivolumab group. The combination of different immune checkpoint inhibitors may also be promising.</p><p class="" id=d15958e867>Ipilimumab is an anti-CTLA4 antibody, tested in the phase I/II study, in combination with nivolumab<sup><a href="#ref-84">84</a></sup>. Patients (n = 160) were randomly assigned to one of three groups: nivolumab alone (3 mg/kg), nivolumab plus ipilimumab (1 and 3 mg/kg, respectively), and nivolumab plus ipilimumab (3 and 1 mg/kg, respectively). Overall response rates (ORRs) were 12%, 24%, and 8% in the first, second, and third groups, respectively, and seemed better in the case of PD-L1 expression. Corresponding median OS values were 6.2, 6.9, and 4.8 months (not reached in PD-L1<sup>+</sup> subgroups). Toxicity was increased with combination therapy (47% of grade 3 or 4 adverse events and treatment discontinuation due to toxicity in 20% of the cases in the second group). A phase III trial is ongoing.</p><p class="" id=d15958e877>Pembrolizumab is another anti-PD-1 antibody, currently tested alone or in combination in three different cohorts in the phase II KEYNOTE-059 study. In cohort 1, patients with advanced gastric and gastroesophageal junction cancer who were progressive after two or more chemotherapy lines received pembrolizumab monotherapy at 200 mg every 3 weeks<sup><a href="#ref-85">85</a></sup>. In total, 259 patients were included (52% in third-line and 48% in fourth-line or more). ORR, the primary endpoint, was 11.6%; interestingly, durable responses were observed in patients with PD-L1-positive cancer (15.5% in PD-L1 positive and 6.4% in PD-L1 negative). Based on these results, pembrolizumab has been approved by the US Food and Drug Administration (FDA) for patients with GAC positive for PD-L1 expression (≥1% labeling index in tumor/immune cells in the presence of at least 100 tumor cells in the specimen) to be used in the third (or later) line. Cohort 2 included treatment-naïve patients who received a combination of pembrolizumab (200 mg/3 weeks) and chemotherapy (cisplatin plus 5-FU or capecitabine). Preliminary results in 25 patients were promising, showing an ORR of 60% and a median PFS of 6.6 months<sup><a href="#ref-86">86</a></sup>. These results suggest that anti-PD1 antibodies can potentiate conventional cytotoxic chemotherapy in the first-line setting. The results from the phase III trial are expected (ClinicalTrials.gov Identifier: NCT02494583)<sup><a href="#ref-87">87</a></sup>.</p><p class="" id=d15958e892>Avelumab is an anti-PD-L1 antibody and was evaluated in the phase Ib JAVELIN trial as a first-line maintenance (group 1) or second-line (group 2) therapy<sup><a href="#ref-88">88</a></sup>. ORRs were 9.0%<i></i> and 9.7% in groups 1 and 2, respectively. The corresponding<i></i> median PFS values were 12.0 and 6.0 weeks. Two phase III trials<i></i> are ongoing with avelumab in metastatic GAC<i></i> or gastroesophageal junction adenocarcinoma. The JAVELIN Gastric 300 evaluated avelumab as a third-line treatment, and 371 patients were randomly assigned to receive avelumab plus BSC or chemotherapy (paclitaxel or irinotecan) plus BSC (ClinicalTrials.gov Identifier: NCT02625623). This trial failed to meet its primary outcome of superior survival, and detailed results are awaited. The JAVELIN Gastric 100 has been evaluating avelumab as a maintenance therapy (ClinicalTrials.gov Identifier: NCT02625610). This trial has completed accrual and results are awaited.</p><p class="" id=d15958e908>The modest efficacy and high cost of immune checkpoint inhibitors suggest that we need a reliable predictive/prognostic biomarker to select these agents. In studies described above, ORR was two to three times higher in the case of PD-L1 positivity in tumor cells. However, results are conflicting, and there is no consensus on the best way to assess PD-L1 status. MSI refers to the replicative error phenotype caused by mutations in the mismatch repair (MMR) system. Recently, Le <i>et al</i>. reported an ORR of 53% in 86 patients with MSI-H tumors, of whom 76% had gastrointestinal cancers<sup><a href="#ref-89">89</a></sup>. After a 2-year follow-up, 53% of the patients had not had tumor progression and 64% were still alive (medians not reached). In the KEYNOTE-059 study (cohort 1), the ORR was 57% in patients with MSI tumors compared with 9% in the case of MSS tumors<sup><a href="#ref-85">85</a></sup>. Based on five trials (KEYNOTE-016, KEYNOTE-164, KEYNOTE-012, KEYNOTE-028, and KEYNOTE-158), pembrolizumab has been approved by the FDA for MSI-H or deficient MMR solid tumors. In preliminary studies, a new generation of immunotherapy drugs is being evaluated for downregulating immunosuppressive pathways (for example, VISTA, an immunosuppressive molecule expressed on regulatory T cells, and indoleamine 2,3-dioxygenase (IDO), an enzyme leading to decreased tryptophan level which then suppresses T-cell proliferation) or stimulating immune tumor response (for example, inducible T-cell co-stimulator [ICOS] agonists)<sup><a href="#ref-90">90</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d15958e929>Conclusions</h2><p class="" id=d15958e932>In summary, in addition to high-quality surgery, preoperative or postoperative chemotherapy is recommended for localized advanced GAC, depending on local preferences (<a href="#T1">Table 1</a>). Preoperative chemoradiation is a non-standard option with potential and is being studied in phase III trials. Only trastuzumab and ramucirumab (in combination) are effective targeted drugs for GAC (<a href="#T2">Table 2</a>). PD-1 inhibitor is highly active against MSI-H GACs. Clearly, more basic research is needed to identify novel targets and drugs.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Preoperative treatment trial for localized gastric adenocarcinoma.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d15958e952 class=n-a></a><thead><a name=d15958e954 class=n-a></a><tr><a name=d15958e956 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e958 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e961 class=n-a></a>Number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e964 class=n-a></a>Treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e967 class=n-a></a>Survival</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e970 class=n-a></a>HR<br class=br>(95% CI)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e976 class=n-a></a><i>p</i> value</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e981 class=n-a></a>Reference</th></tr></thead><tbody><a name=d15958e986 class=n-a></a><tr><a name=d15958e988 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e990 class=n-a></a>ACTS-GC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e993 class=n-a></a>n = 529<br class=br>n = 530</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e998 class=n-a></a>Surgery → S-1<br class=br>Surgery</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1003 class=n-a></a>5-year OS: 72%<br class=br>5-year OS: 61%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1008 class=n-a></a>0.67<br class=br>(0.54–0.82)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1014 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1017 class=n-a></a><a href="#ref-11">11</a></td></tr><tr><a name=d15958e1022 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1024 class=n-a></a>CLASSIC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1027 class=n-a></a>n = 520<br class=br>n = 515</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1032 class=n-a></a>Surgery → XP<br class=br>Surgery</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1037 class=n-a></a>5-year OS: 78%<br class=br>5-year OS: 69%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1042 class=n-a></a>0.66<br class=br>(0.51–0.85)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1048 class=n-a></a>0.0015</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1051 class=n-a></a><a href="#ref-12">12</a></td></tr><tr><a name=d15958e1056 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1058 class=n-a></a>ITACA-S</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1061 class=n-a></a>n = 562<br class=br>n = 538</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1066 class=n-a></a>Surgery → FOLFIRI → DP<br class=br>Surgery → 5-FU/LV</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1071 class=n-a></a>5-year OS: 51%<br class=br>5-year OS: 51%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1076 class=n-a></a>0.98<br class=br>(0.82–1.18)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1082 class=n-a></a>0.87</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1085 class=n-a></a><a href="#ref-13">13</a></td></tr><tr><a name=d15958e1090 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1092 class=n-a></a>INT-0116</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1095 class=n-a></a>n = 281<br class=br>n = 275</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1100 class=n-a></a>Surgery → 5-FU/45 Gy<br class=br>Surgery</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1105 class=n-a></a>Median OS: 36 months<br class=br>Median OS: 27 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1110 class=n-a></a>1.35<br class=br>(1.09–1.66)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1116 class=n-a></a>0.005</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1119 class=n-a></a><a href="#ref-16">16</a></td></tr><tr><a name=d15958e1124 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1126 class=n-a></a>ARTIST</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1129 class=n-a></a>n = 228<br class=br>n = 230</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1134 class=n-a></a>Surgery → XP<br class=br>Surgery → XP/45 Gy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1139 class=n-a></a>3-year DFS: 74%<br class=br>3-year DFS: 78%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1144 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1148 class=n-a></a>0.86</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1151 class=n-a></a><a href="#ref-18">18</a></td></tr><tr><a name=d15958e1157 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1159 class=n-a></a>CRITICS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1162 class=n-a></a>n = 393<br class=br>n = 395</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1167 class=n-a></a>ECC → Surgery → ECC<br class=br>ECC → Surgery → ECC/45 Gy</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1172 class=n-a></a>5-year OS: 41%<br class=br>5-year OS: 41%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1177 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1181 class=n-a></a>0.99</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1184 class=n-a></a><a href="#ref-19">19</a></td></tr><tr><a name=d15958e1189 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1191 class=n-a></a>FNCLCC/FFCD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1194 class=n-a></a>n = 113<br class=br>n = 111</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1199 class=n-a></a>CF → Surgery (n = 113)<br class=br>Surgery (n = 111)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1204 class=n-a></a>5-year OS: 38%<br class=br>5-year OS: 24%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1209 class=n-a></a>0.69<br class=br>(0.50–0.95)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1215 class=n-a></a>0.02</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1218 class=n-a></a><a href="#ref-22">22</a></td></tr><tr><a name=d15958e1223 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1225 class=n-a></a>MAGIC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1228 class=n-a></a>n = 250<br class=br>n = 253</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1233 class=n-a></a>ECF → Surgery → ECF<br class=br>Surgery</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1238 class=n-a></a>5-year OS: 36%<br class=br>5-year OS: 23%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1243 class=n-a></a>0.75<br class=br>(0.60–0.93)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1249 class=n-a></a>0.009</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1252 class=n-a></a><a href="#ref-20">20</a></td></tr><tr><a name=d15958e1257 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1259 class=n-a></a>MRC<br class=br>OEO-5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1264 class=n-a></a>n = 446<br class=br>n = 451</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1269 class=n-a></a>ECF → Surgery<br class=br>CF → Surgery</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1274 class=n-a></a>3-year OS: 39%<br class=br>3-year OS: 42%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1279 class=n-a></a>0.92<br class=br>(0.79–1.08)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1285 class=n-a></a>0.30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1288 class=n-a></a><a href="#ref-23">23</a></td></tr><tr><a name=d15958e1293 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1295 class=n-a></a>FLOT4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1298 class=n-a></a>n = 360<br class=br>n = 356</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1303 class=n-a></a>ECF → Surgery → ECF<br class=br>FLOT → Surgery → FLOT</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1308 class=n-a></a>3-year OS: 48%<br class=br>3-year OS: 57%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1313 class=n-a></a>0.77<br class=br>(0.63–0.94)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1319 class=n-a></a>0.012</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1322 class=n-a></a><a href="#ref-25">25</a></td></tr><tr><a name=d15958e1327 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1329 class=n-a></a>ST03</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1332 class=n-a></a>n = 533<br class=br>n = 530</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1337 class=n-a></a>ECF → Surgery → ECF<br class=br>ECF+Bev → Surgery → ECF+Bev</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1342 class=n-a></a>3-year OS: 50%<br class=br>3-year OS: 48%</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1347 class=n-a></a>1.08<br class=br>(0.91–1.29)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1353 class=n-a></a>0.36</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1356 class=n-a></a><a href="#ref-26">26</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d15958e1365 class=n-a></a><p id=d15958e1367> 5-FU, 5-fluorouracil; Bev, bevacizumab; CF, cisplatin and 5-fluorouracil; CI, confidence interval; ECC, epirubicin, cisplatin, and capecitabine; ECF, epirubicin, cisplatin, and 5-fluorouracil; FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil; Gy, Gray; HR, hazard rate; OS, overall survival; XP, cisplatin and capecitabine.</p></div></div></div><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Targeted therapy trial for metastatic gastric adenocarcinoma.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d15958e1384 class=n-a></a><thead><a name=d15958e1386 class=n-a></a><tr><a name=d15958e1388 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e1390 class=n-a></a>Study</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e1393 class=n-a></a>Number</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e1396 class=n-a></a>Target</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e1399 class=n-a></a>Treatment</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e1402 class=n-a></a>Survival</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e1406 class=n-a></a>HR<br class=br>(95% CI)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d15958e1411 class=n-a></a>Reference</th></tr><tr><a name=d15958e1415 class=n-a></a><th align=center colspan=7 rowspan=1 valign=top><a name=d15958e1417 class=n-a></a>First-line setting</th></tr></thead><tbody><a name=d15958e1422 class=n-a></a><tr><a name=d15958e1424 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1426 class=n-a></a>ToGA</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1429 class=n-a></a>n = 298<br class=br>n = 296</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1434 class=n-a></a>HER2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1437 class=n-a></a>Trastuzumab + XP<br class=br>Placebo + XP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1442 class=n-a></a>mOS: 13.8 months<br class=br>mOS: 11.1 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1448 class=n-a></a>0.74<br class=br>(0.60–0.91)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1453 class=n-a></a><a href="#ref-34">34</a></td></tr><tr><a name=d15958e1458 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1460 class=n-a></a>TRIO-013/LOGiC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1463 class=n-a></a>n = 249<br class=br>n = 238</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1468 class=n-a></a>HER2/EGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1471 class=n-a></a>Lapatinib + CapeOx<br class=br>Placebo + CapeOx</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1476 class=n-a></a>mOS: 12.2 months<br class=br>mOS: 10.5 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1482 class=n-a></a>0.91<br class=br>(0.73–1.12)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1487 class=n-a></a><a href="#ref-59">59</a></td></tr><tr><a name=d15958e1492 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1494 class=n-a></a>EXPAND</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1497 class=n-a></a>n = 455<br class=br>n = 449</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1502 class=n-a></a>EGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1505 class=n-a></a>Cetuximab + XP<br class=br>Placebo + XP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1510 class=n-a></a>mOS: 9.4 months<br class=br>mOS: 10.7 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1516 class=n-a></a>1.00<br class=br>(0.87–1.17)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1521 class=n-a></a><a href="#ref-61">61</a></td></tr><tr><a name=d15958e1526 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1528 class=n-a></a>REAL3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1531 class=n-a></a>n = 278<br class=br>n = 275</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1536 class=n-a></a>EGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1539 class=n-a></a>Panitumumab + EOC<br class=br>Placebo + EOC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1544 class=n-a></a>mOS: 8.8 months<br class=br>mOS: 11.3 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1550 class=n-a></a>1.37<br class=br>(1.07–1.76)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1555 class=n-a></a><a href="#ref-62">62</a></td></tr><tr><a name=d15958e1560 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1562 class=n-a></a>AVAGAST</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1565 class=n-a></a>n = 387<br class=br>n = 387</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1570 class=n-a></a>VEGF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1573 class=n-a></a>Bevacizumab + FP<br class=br>Placebo + FP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1578 class=n-a></a>mOS: 12.1 months<br class=br>mOS: 10.1 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1584 class=n-a></a>0.87<br class=br>(0.73–1.03)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1589 class=n-a></a><a href="#ref-64">64</a></td></tr><tr><a name=d15958e1595 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1597 class=n-a></a>RAINFALL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1600 class=n-a></a>n = 326<br class=br>n = 319</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1605 class=n-a></a>VEGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1608 class=n-a></a>Ramucirumab + Cape/Cis<br class=br>Placebo + Cape/Cis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1613 class=n-a></a>mOS: 11.2 months<br class=br>mOS: 10.7 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1619 class=n-a></a>0.68<br class=br>(0.80–1.16)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1624 class=n-a></a><a href="#ref-63">63</a></td></tr><tr><a name=d15958e1629 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1631 class=n-a></a>RILOMET-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1634 class=n-a></a>n = 304<br class=br>n = 305</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1639 class=n-a></a>MET</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1642 class=n-a></a>Rilotumumab + ECX<br class=br>Placebo + ECX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1647 class=n-a></a>mOS: 8.8 months<br class=br>mOS: 10.7 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1653 class=n-a></a>1.34<br class=br>(1.10–1.63)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1658 class=n-a></a><a href="#ref-65">65</a></td></tr><tr><a name=d15958e1663 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1665 class=n-a></a>METGastric</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1668 class=n-a></a>n = 279<br class=br>n = 283</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1673 class=n-a></a>MET</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1676 class=n-a></a>Onartuzumab + FOLFOX<br class=br>Placebo + FOLFOX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1681 class=n-a></a>mOS: 11.0 months<br class=br>mOS: 11.3 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1687 class=n-a></a>0.82<br class=br>(0.59–1.15)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1692 class=n-a></a><a href="#ref-66">66</a></td></tr><tr><a name=d15958e1697 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1699 class=n-a></a>Cohen <i>et al</i>.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1705 class=n-a></a>n = 60<br class=br>n = 63</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1710 class=n-a></a>Hedgehog<br class=br>pathway</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1715 class=n-a></a>Vismodegib + FOLFOX<br class=br>Placebo + FOLFOX6</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1720 class=n-a></a>mOS: 11.5 months<br class=br>mOS: 14.9 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1726 class=n-a></a>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1729 class=n-a></a><a href="#ref-74">74</a></td></tr><tr><a name=d15958e1734 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1736 class=n-a></a>FAST</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1739 class=n-a></a>n =84<br class=br>n =77</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1744 class=n-a></a>Claudin18.2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1747 class=n-a></a>IMAB362 + EOX<br class=br>Placebo + EOX</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1752 class=n-a></a>mOS: 13.2 months<br class=br>mOS: 8.4 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1758 class=n-a></a>0.51<br class=br>(0.36–0.73)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1763 class=n-a></a><a href="#ref-78">78</a></td></tr><tr><a name=d15958e1768 class=n-a></a><th align=center colspan=7 rowspan=1 valign=top><a name=d15958e1770 class=n-a></a>Beyond second-line setting</th></tr><tr><a name=d15958e1775 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1777 class=n-a></a>REGARD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1780 class=n-a></a>n = 238<br class=br>n = 117</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1785 class=n-a></a>VEGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1788 class=n-a></a>Ramucirumab<br class=br>Placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1793 class=n-a></a>mOS: 5.2 months<br class=br>mOS: 3.8 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1799 class=n-a></a>0.78<br class=br>(0.60–0.99)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1804 class=n-a></a><a href="#ref-46">46</a></td></tr><tr><a name=d15958e1809 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1811 class=n-a></a>RAINBOW</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1814 class=n-a></a>n = 330<br class=br>n = 335</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1819 class=n-a></a>VEGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1822 class=n-a></a>Ramucirumab + paclitaxel<br class=br>Placebo + paclitaxel</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1827 class=n-a></a>mOS: 9.6 months<br class=br>mOS: 7.4 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1833 class=n-a></a>0.81<br class=br>(0.68–0.96)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1838 class=n-a></a><a href="#ref-45">45</a></td></tr><tr><a name=d15958e1843 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1845 class=n-a></a>GATSBY</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1848 class=n-a></a>n = 228<br class=br>n = 117</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1853 class=n-a></a>HER2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1856 class=n-a></a>Trastuzumab emtansine<br class=br>Taxane</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1861 class=n-a></a>mOS: 7.9 months<br class=br>mOS: 8.6 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1867 class=n-a></a>1.15<br class=br>(0.87–1.51)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1872 class=n-a></a><a href="#ref-58">58</a></td></tr><tr><a name=d15958e1877 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1879 class=n-a></a>TyTAN</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1882 class=n-a></a>n = 132<br class=br>n = 129</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1887 class=n-a></a>HER2/EGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1890 class=n-a></a>Lapatinib + paclitaxel<br class=br>Placebo + paclitaxel</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1895 class=n-a></a>mOS: 11.0 months<br class=br>mOS: 8.9 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1901 class=n-a></a>0.84<br class=br>(0.64–1.11)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1906 class=n-a></a><a href="#ref-60">60</a></td></tr><tr><a name=d15958e1911 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1913 class=n-a></a>GRANITE-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1916 class=n-a></a>n = 439<br class=br>n = 217</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1921 class=n-a></a>mTOR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1924 class=n-a></a>Everolimus<br class=br>Placebo</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1929 class=n-a></a>mOS: 5.9 months<br class=br>mOS: 4.3 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1935 class=n-a></a>0.90<br class=br>(0.75–1.08)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1940 class=n-a></a><a href="#ref-67">67</a></td></tr><tr><a name=d15958e1945 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1947 class=n-a></a>RADPAC</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1950 class=n-a></a>n = 150<br class=br>n = 150</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1955 class=n-a></a>mTOR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1958 class=n-a></a>Everolimus + paclitaxel<br class=br>Placebo + paclitaxel</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1963 class=n-a></a>mOS: 6.1 months<br class=br>mOS: 5.1 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1969 class=n-a></a>0.92<br class=br>-</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1974 class=n-a></a><a href="#ref-68">68</a></td></tr><tr><a name=d15958e1980 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1982 class=n-a></a>SHINE</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1985 class=n-a></a>n = 41<br class=br>n = 30</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1990 class=n-a></a>FGFR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1993 class=n-a></a>AZD4547<br class=br>paclitaxel</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e1998 class=n-a></a>mOS: 5.5 months<br class=br>mOS: 6.6 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2004 class=n-a></a>1.31<br class=br>(0.89–1.95)<sup><a href="#FN1">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2012 class=n-a></a><a href="#ref-69">69</a></td></tr><tr><a name=d15958e2017 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2019 class=n-a></a>GOLD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2022 class=n-a></a>n = 263<br class=br>n = 262</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2027 class=n-a></a>PARP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2030 class=n-a></a>Olaparib + paclitaxel<br class=br>Placebo + paclitaxel</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2035 class=n-a></a>mOS: 8.8 months<br class=br>mOS: 6.9 months</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2041 class=n-a></a>0.79<br class=br>(0.63–1.00)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d15958e2046 class=n-a></a><a href="#ref-72">72</a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d15958e2055 class=n-a></a><p id=FN1> <sup>a</sup>80% confidence interval. Cape/Cis, capecitabine and cisplatin; CapeOx, capecitabine and oxaliplatin; CI, confidence interval; ECX, epirubicin, cisplatin, and capecitabine; EGFR, epidermal growth factor receptor; EOC/EOX, epirubicin, oxaliplatin, and capecitabine; FGFR, fibroblast growth factor receptor; FOLFOX, leucovorin, 5-fluorouracil, and oxaliplatin; FP, cisplatin and 5-fluorouracil; HER2, human epidermal growth factor receptor 2; HR, hazard rate; MET, mesenchymal–epithelial transition; mOS, median overall survival; mTOR, mammalian target of rapamycin; PARP, poly (ADP-ribose) polymerase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; XP, cisplatin and capecitabine.</p></div></div></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d15958e1 class=n-a></a><h2 class=main-title id=d16278>Author contributions</h2><p class=metadata-entry><a name=d15958e175 class=n-a></a><p id=d15958e177> KH, AL, and JA conceived the article. KH, NS, BB, HB, and AL prepared the first draft of the manuscript. All authors contributed to the preparation of the manuscript, were involved in the revision of the draft manuscript, and have agreed to the final content.</p></p></div><div class=back-section><a name=d15958e1 class=n-a></a><h2 class=main-title id=d16280>Grant information</h2><p>This research was supported by generous grants from the Caporella, Dallas, Sultan, Park, Smith, Frazier, Oaks, Vanstekelenberg, Planjery, and Cantu families as well as from the Schecter Private Foundation, Rivercreek Foundation, Kevin Fund, Myer Fund, Dio Fund, Milrod Fund, and the University of Texas M.D. Anderson Cancer Center (Houston, TX, USA) multidisciplinary grant program. This research was also supported in part by the National Cancer Institute and Department of Defense awards CA138671, CA172741, CA129926, and CA150334 (JA) and by a grant from the Japan Society for the Promotion of Science Overseas Research Fellowships and Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (KH).</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d15958e2070 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d16555>References</h2><div class="section ref-list"><a name=d15958e2070 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d15958e2077 class=n-a></a>Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, <i> et al.</i>: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. <i>JAMA Oncol.</i> 2017; <b>3</b>(4): 524–48. <a target=xrefwindow id=d15958e2088 href="http://www.ncbi.nlm.nih.gov/pubmed/27918777">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2091 href="http://dx.doi.org/10.1001/jamaoncol.2016.5688">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d15958e2100 class=n-a></a>Crew KD, Neugut AI: Epidemiology of gastric cancer. <i>World J Gastroenterol.</i> 2006; <b>12</b>(3): 354–62. <a target=xrefwindow id=d15958e2108 href="http://www.ncbi.nlm.nih.gov/pubmed/16489633">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2111 href="http://dx.doi.org/10.3748/wjg.v12.i3.354">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2114 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4066052">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d15958e2123 class=n-a></a>Blot WJ, Devesa SS, Kneller RW, <i> et al.</i>: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. <i>JAMA.</i> 1991; <b>265</b>(10): 1287–9. <a target=xrefwindow id=d15958e2134 href="http://www.ncbi.nlm.nih.gov/pubmed/1995976">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2137 href="http://dx.doi.org/10.1001/jama.1991.03460100089030">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d15958e2146 class=n-a></a>Cristescu R, Lee J, Nebozhyn M, <i> et al.</i>: Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. <i>Nat Med.</i> 2015; <b>21</b>(5): 449–56. <a target=xrefwindow id=d15958e2157 href="http://www.ncbi.nlm.nih.gov/pubmed/25894828">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2160 href="http://dx.doi.org/10.1038/nm.3850">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718513254"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2169 class=n-a></a>Cancer Genome Atlas Research Network: Comprehensive molecular characterization of gastric adenocarcinoma. <i>Nature.</i> 2014; <b>513</b>(7517): 202–9. <a target=xrefwindow id=d15958e2177 href="http://www.ncbi.nlm.nih.gov/pubmed/25079317">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2180 href="http://dx.doi.org/10.1038/nature13480">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2183 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4170219">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718513254">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732946620"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2197 class=n-a></a>Liu Y, Sethi NS, Hinoue T, <i> et al.</i>: Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell.</i> 2018; <b>33</b>(4): 721–735.e8. <a target=xrefwindow id=d15958e2208 href="http://www.ncbi.nlm.nih.gov/pubmed/29622466">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2211 href="http://dx.doi.org/10.1016/j.ccell.2018.03.010">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2215 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5966039">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732946620">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d15958e2228 class=n-a></a>Sohn BH, Hwang JE, Jang HJ, <i> et al.</i>: Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. <i>Clin Cancer Res.</i> 2017; <b>23</b>(15): 4441–9. <a target=xrefwindow id=d15958e2239 href="http://www.ncbi.nlm.nih.gov/pubmed/28747339">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2242 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-2211">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2246 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5785562">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d15958e2255 class=n-a></a>Saeterdal I, Bjørheim J, Lislerud K, <i> et al.</i>: Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. <i>Proc Natl Acad Sci U S A.</i> 2001; <b>98</b>(23): 13255–60. <a target=xrefwindow id=d15958e2266 href="http://www.ncbi.nlm.nih.gov/pubmed/11687624">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2269 href="http://dx.doi.org/10.1073/pnas.231326898">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2273 href="http://www.ncbi.nlm.nih.gov/pmc/articles/60857">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726366095"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2282 class=n-a></a>Colli LM, Machiela MJ, Myers TA, <i> et al.</i>: Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. <i>Cancer Res.</i> 2016; <b>76</b>(13): 3767–72. <a target=xrefwindow id=d15958e2293 href="http://www.ncbi.nlm.nih.gov/pubmed/27197178">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2296 href="http://dx.doi.org/10.1158/0008-5472.CAN-16-0170">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2300 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4930685">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726366095">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726993872"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2313 class=n-a></a>Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2014 (ver. 4). <i>Gastric Cancer.</i> 2017; <b>20</b>(1): 1–19. <a target=xrefwindow id=d15958e2321 href="http://www.ncbi.nlm.nih.gov/pubmed/27342689">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2324 href="http://dx.doi.org/10.1007/s10120-016-0622-4">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2327 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5215069">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726993872">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13398993"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2340 class=n-a></a>Sasako M, Sakuramoto S, Katai H, <i> et al.</i>: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. <i>J Clin Oncol.</i> 2011; <b>29</b>(33): 4387–93. <a target=xrefwindow id=d15958e2351 href="http://www.ncbi.nlm.nih.gov/pubmed/22010012">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2354 href="http://dx.doi.org/10.1200/JCO.2011.36.5908">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13398993">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d15958e2368 class=n-a></a>Noh SH, Park SR, Yang HK, <i> et al.</i>: Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(12): 1389–96. <a target=xrefwindow id=d15958e2379 href="http://www.ncbi.nlm.nih.gov/pubmed/25439693">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2382 href="http://dx.doi.org/10.1016/S1470-2045(14)70473-5">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d15958e2391 class=n-a></a>Bajetta E, Floriani I, Di Bartolomeo M, <i> et al.</i>: Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. <i>Ann Oncol.</i> 2014; <b>25</b>(7): 1373–8. <a target=xrefwindow id=d15958e2402 href="http://www.ncbi.nlm.nih.gov/pubmed/24728035">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2405 href="http://dx.doi.org/10.1093/annonc/mdu146">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d15958e2414 class=n-a></a>Cascinu S, Labianca R, Barone C, <i> et al.</i>: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. <i>J Natl Cancer Inst.</i> 2007; <b>99</b>(8): 601–7. <a target=xrefwindow id=d15958e2425 href="http://www.ncbi.nlm.nih.gov/pubmed/17440161">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2428 href="http://dx.doi.org/10.1093/jnci/djk131">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d15958e2437 class=n-a></a>Kodera Y, Yoshida K, Kochi M, <i> et al.</i>: A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial). <i>J Clin Oncol.</i> 2018; <b>36</b>(15_suppl): abstr 4007. <a target=xrefwindow id=d15958e2448 href="http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4007">Reference Source</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d15958e2457 class=n-a></a>Macdonald JS, Smalley SR, Benedetti J, <i> et al.</i>: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. <i>N Engl J Med.</i> 2001; <b>345</b>(10): 725–30. <a target=xrefwindow id=d15958e2468 href="http://www.ncbi.nlm.nih.gov/pubmed/11547741">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2471 href="http://dx.doi.org/10.1056/NEJMoa010187">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717447802"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2480 class=n-a></a>Smalley SR, Benedetti JK, Haller DG, <i> et al.</i>: Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. <i>J Clin Oncol.</i> 2012; <b>30</b>(19): 2327–33. <a target=xrefwindow id=d15958e2491 href="http://www.ncbi.nlm.nih.gov/pubmed/22585691">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2494 href="http://dx.doi.org/10.1200/JCO.2011.36.7136">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2498 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4517071">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717447802">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14208981"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2512 class=n-a></a>Lee J, Lim DH, Kim S, <i> et al.</i>: Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. <i>J Clin Oncol.</i> 2012; <b>30</b>(3): 268–73. <a target=xrefwindow id=d15958e2523 href="http://www.ncbi.nlm.nih.gov/pubmed/22184384">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2526 href="http://dx.doi.org/10.1200/JCO.2011.39.1953">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14208981">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d15958e2539 class=n-a></a>Verheij M, Jansen EP, Cats A, <i> et al.</i>: A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. <i>J Clin Oncol.</i> 2016; <b>34</b>(15_suppl): 4000. <a target=xrefwindow id=d15958e2550 href="http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.4000">Reference Source</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14646"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2559 class=n-a></a>Cunningham D, Allum WH, Stenning SP, <i> et al.</i>: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. <i>N Engl J Med.</i> 2006; <b>355</b>(1): 11–20. <a target=xrefwindow id=d15958e2570 href="http://www.ncbi.nlm.nih.gov/pubmed/16822992">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2573 href="http://dx.doi.org/10.1056/NEJMoa055531">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14646">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d15958e2586 class=n-a></a>Elimova E, Janjigian YY, Mulcahy M, <i> et al.</i>: It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. <i>J Clin Oncol.</i> 2017; <b>35</b>(4): 475–7. <a target=xrefwindow id=d15958e2597 href="http://www.ncbi.nlm.nih.gov/pubmed/28129519">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2600 href="http://dx.doi.org/10.1200/JCO.2016.69.7276">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10541957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2609 class=n-a></a>Ychou M, Boige V, Pignon JP, <i> et al.</i>: Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. <i>J Clin Oncol.</i> 2011; <b>29</b>(13): 1715–21. <a target=xrefwindow id=d15958e2620 href="http://www.ncbi.nlm.nih.gov/pubmed/21444866">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2623 href="http://dx.doi.org/10.1200/JCO.2010.33.0597">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10541957">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d15958e2636 class=n-a></a>Alderson D, Langley RE, Nankivell MG, <i> et al.</i>: Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). <i>J Clin Oncol.</i> 2015; <b>33</b>(15_suppl): 4002. <a target=xrefwindow id=d15958e2647 href="http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.4002">Reference Source</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d15958e2657 class=n-a></a>Al-Batran SE, Pauligk C, Homann N, <i> et al.</i>: LBA27_PRDocetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) for resectable esophagogastric cancer: Updated results from multicenter, randomized phase 3 FLOT4-AIO trial (German Gastric Group at AIO). <i>Ann Oncol.</i> 2017; <b>28</b>(suppl_5): mdx440.019. <a target=xrefwindow id=d15958e2668 href="http://dx.doi.org/10.1093/annonc/mdx440.019">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d15958e2677 class=n-a></a>Al-Batran SE, Homann N, Schmalenberg H, <i> et al.</i>: Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. <i>J Clin Oncol.</i> 2017; <b>35</b>(15_suppl): 4004. <a target=xrefwindow id=d15958e2688 href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4004">Reference Source</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727280544"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2697 class=n-a></a>Cunningham D, Stenning SP, Smyth EC, <i> et al.</i>: Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): Primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(3): 357–70. <a target=xrefwindow id=d15958e2708 href="http://www.ncbi.nlm.nih.gov/pubmed/28163000">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2711 href="http://dx.doi.org/10.1016/S1470-2045(17)30043-8">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2715 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5337626">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727280544">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717147902"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2728 class=n-a></a>van Hagen P, Hulshof MC, van Lanschot JJ, <i> et al.</i>: Preoperative chemoradiotherapy for esophageal or junctional cancer. <i>N Engl J Med.</i> 2012; <b>366</b>(22): 2074–84. <a target=xrefwindow id=d15958e2739 href="http://www.ncbi.nlm.nih.gov/pubmed/22646630">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2742 href="http://dx.doi.org/10.1056/NEJMoa1112088">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717147902">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d15958e2755 class=n-a></a>Ajani JA, D'Amico TA, Almhanna K, <i> et al.</i>: Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. <i>J Natl Compr Canc Netw.</i> 2016; <b>14</b>(10): 1286–312. <a target=xrefwindow id=d15958e2766 href="http://www.ncbi.nlm.nih.gov/pubmed/27697982">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2769 href="http://dx.doi.org/10.6004/jnccn.2016.0137">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d15958e2778 class=n-a></a>Ajani JA, Mansfield PF, Crane CH, <i> et al.</i>: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. <i>J Clin Oncol.</i> 2005; <b>23</b>(6): 1237–44. <a target=xrefwindow id=d15958e2789 href="http://www.ncbi.nlm.nih.gov/pubmed/15718321">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2792 href="http://dx.doi.org/10.1200/JCO.2005.01.305">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d15958e2802 class=n-a></a>Ajani JA, Mansfield PF, Janjan N, <i> et al.</i>: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. <i>J Clin Oncol.</i> 2004; <b>22</b>(14): 2774–80. <a target=xrefwindow id=d15958e2813 href="http://www.ncbi.nlm.nih.gov/pubmed/15254045">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2816 href="http://dx.doi.org/10.1200/JCO.2004.01.015">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d15958e2825 class=n-a></a>Ajani JA, Winter K, Okawara GS, <i> et al.</i>: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. <i>J Clin Oncol.</i> 2006; <b>24</b>(24): 3953–8. <a target=xrefwindow id=d15958e2836 href="http://www.ncbi.nlm.nih.gov/pubmed/16921048">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2839 href="http://dx.doi.org/10.1200/JCO.2006.06.4840">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d15958e2848 class=n-a></a>Elimova E, Slack RS, Chen HC, <i> et al.</i>: Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. <i>Oncotarget.</i> 2017; <b>8</b>(46): 81430–40. <a target=xrefwindow id=d15958e2859 href="http://www.ncbi.nlm.nih.gov/pubmed/29113402">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2862 href="http://dx.doi.org/10.18632/oncotarget.19226">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2866 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5655297">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d15958e2875 class=n-a></a>Leong T, Smithers BM, Michael M, <i> et al.</i>: <i>TOPGEAR</i>: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). <i>BMC Cancer.</i> 2015; <b>15</b>: 532. <a target=xrefwindow id=d15958e2889 href="http://www.ncbi.nlm.nih.gov/pubmed/26194186">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2893 href="http://dx.doi.org/10.1186/s12885-015-1529-x">Publisher Full Text </a> | <a target=xrefwindow id=d15958e2896 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4507314">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5004956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e2905 class=n-a></a>Bang YJ, Van Cutsem E, Feyereislova A, <i> et al.</i>: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. <i>Lancet.</i> 2010; <b>376</b>(9742): 687–97. <a target=xrefwindow id=d15958e2916 href="http://www.ncbi.nlm.nih.gov/pubmed/20728210">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2919 href="http://dx.doi.org/10.1016/S0140-6736(10)61121-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5004956">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d15958e2932 class=n-a></a>Guimbaud R, Louvet C, Ries P, <i> et al.</i>: Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. <i>J Clin Oncol.</i> 2014; <b>32</b>(31): 3520–6. <a target=xrefwindow id=d15958e2943 href="http://www.ncbi.nlm.nih.gov/pubmed/25287828">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2946 href="http://dx.doi.org/10.1200/JCO.2013.54.1011">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d15958e2956 class=n-a></a>Ajani JA, Baker J, Pisters PW, <i> et al.</i>: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. <i>Cancer.</i> 2002; <b>94</b>(3): 641–6. <a target=xrefwindow id=d15958e2967 href="http://www.ncbi.nlm.nih.gov/pubmed/11857295">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2970 href="http://dx.doi.org/10.1002/cncr.10279">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d15958e2979 class=n-a></a>Dank M, Zaluski J, Barone C, <i> et al.</i>: Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. <i>Ann Oncol.</i> 2008; <b>19</b>(8): 1450–7. <a target=xrefwindow id=d15958e2990 href="http://www.ncbi.nlm.nih.gov/pubmed/18558665">PubMed Abstract </a> | <a target=xrefwindow id=d15958e2993 href="http://dx.doi.org/10.1093/annonc/mdn166">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d15958e3002 class=n-a></a>Van Cutsem E, Moiseyenko VM, Tjulandin S, <i> et al.</i>: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. <i>J Clin Oncol.</i> 2006; <b>24</b>(31): 4991–7. <a target=xrefwindow id=d15958e3013 href="http://www.ncbi.nlm.nih.gov/pubmed/17075117">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3016 href="http://dx.doi.org/10.1200/JCO.2006.06.8429">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d15958e3025 class=n-a></a>Ajani JA, Fodor MB, Tjulandin SA, <i> et al.</i>: Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. <i>J Clin Oncol.</i> 2005; <b>23</b>(24): 5660–7. <a target=xrefwindow id=d15958e3036 href="http://www.ncbi.nlm.nih.gov/pubmed/16110025">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3039 href="http://dx.doi.org/10.1200/JCO.2005.17.376">Publisher Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d15958e3048 class=n-a></a>Blum Murphy MA, Qiao W, Mewada N, <i> et al.</i>: A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. <i>Am J Clin Oncol.</i> 2018; <b>41</b>(4): 321–5. <a target=xrefwindow id=d15958e3059 href="http://www.ncbi.nlm.nih.gov/pubmed/26908161">PubMed Abstract </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d15958e3068 class=n-a></a>Al-Batran SE, Hartmann JT, Hofheinz R, <i> et al.</i>: Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. <i>Ann Oncol.</i> 2008; <b>19</b>(11): 1882–7. <a target=xrefwindow id=d15958e3079 href="http://www.ncbi.nlm.nih.gov/pubmed/18669868">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3082 href="http://dx.doi.org/10.1093/annonc/mdn403">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d15958e3092 class=n-a></a>Van Cutsem E, Boni C, Tabernero J, <i> et al.</i>: Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. <i>Ann Oncol.</i> 2015; <b>26</b>(1): 149–56. <a target=xrefwindow id=d15958e3103 href="http://www.ncbi.nlm.nih.gov/pubmed/25416687">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3106 href="http://dx.doi.org/10.1093/annonc/mdu496">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d15958e3115 class=n-a></a>Shah MA, Janjigian YY, Stoller R, <i> et al.</i>: Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. <i>J Clin Oncol.</i> 2015; <b>33</b>(33): 3874–9. <a target=xrefwindow id=d15958e3126 href="http://www.ncbi.nlm.nih.gov/pubmed/26438119">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3129 href="http://dx.doi.org/10.1200/JCO.2015.60.7465">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d15958e3138 class=n-a></a>Elimova E, Ajani JA: Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? <i>J Clin Oncol.</i> 2015; <b>33</b>(21): 2410. <a target=xrefwindow id=d15958e3146 href="http://www.ncbi.nlm.nih.gov/pubmed/26077236">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3149 href="http://dx.doi.org/10.1200/JCO.2014.59.8847">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d15958e3158 class=n-a></a>Wilke H, Muro K, Van Cutsem E, <i> et al.</i>: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(11): 1224–35. <a target=xrefwindow id=d15958e3169 href="http://www.ncbi.nlm.nih.gov/pubmed/25240821">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3172 href="http://dx.doi.org/10.1016/S1470-2045(14)70420-6">Publisher Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d15958e3181 class=n-a></a>Fuchs CS, Tomasek J, Yong CJ, <i> et al.</i>: Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2014; <b>383</b>(9911): 31–9. <a target=xrefwindow id=d15958e3192 href="http://www.ncbi.nlm.nih.gov/pubmed/24094768">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3195 href="http://dx.doi.org/10.1016/S0140-6736(13)61719-5">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d15958e3204 class=n-a></a>Ajani JA, Lee J, Sano T, <i> et al.</i>: Gastric adenocarcinoma. <i>Nat Rev Dis Primers.</i> 2017; <b>3</b>: 17036. <a target=xrefwindow id=d15958e3215 href="http://www.ncbi.nlm.nih.gov/pubmed/28569272">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3218 href="http://dx.doi.org/10.1038/nrdp.2017.36">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d15958e3228 class=n-a></a>Thuss-Patience PC, Kretzschmar A, Bichev D, <i> et al.</i>: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>Eur J Cancer.</i> 2011; <b>47</b>(15): 2306–14. <a target=xrefwindow id=d15958e3239 href="http://www.ncbi.nlm.nih.gov/pubmed/21742485">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3242 href="http://dx.doi.org/10.1016/j.ejca.2011.06.002">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d15958e3251 class=n-a></a>Kang JH, Lee SI, Lim DH, <i> et al.</i>: Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. <i>J Clin Oncol.</i> 2012; <b>30</b>(13): 1513–8. <a target=xrefwindow id=d15958e3262 href="http://www.ncbi.nlm.nih.gov/pubmed/22412140">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3265 href="http://dx.doi.org/10.1200/JCO.2011.39.4585">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d15958e3274 class=n-a></a>Hironaka S, Ueda S, Yasui H, <i> et al.</i>: Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. <i>J Clin Oncol.</i> 2013; <b>31</b>(35): 4438–44. <a target=xrefwindow id=d15958e3285 href="http://www.ncbi.nlm.nih.gov/pubmed/24190112">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3288 href="http://dx.doi.org/10.1200/JCO.2012.48.5805">Publisher Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d15958e3297 class=n-a></a>Ishigami H, Fujiwara Y, Fukushima R, <i> et al.</i>: Phase III study of intraperitoneal paclitaxel plus s-1/paclitaxel compared with s-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial. <i>J Clin Oncol.</i> 2016; <b>34</b>(15_suppl): 4014. <a target=xrefwindow id=d15958e3308 href="http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.4014">Reference Source</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d15958e3317 class=n-a></a>Ishigami H, Yamaguchi H, Yamashita H, <i> et al.</i>: Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. <i>Gastric Cancer.</i> 2017; <b>20</b>(Suppl 1): 128–34. <a target=xrefwindow id=d15958e3328 href="http://www.ncbi.nlm.nih.gov/pubmed/28028665">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3331 href="http://dx.doi.org/10.1007/s10120-016-0684-3">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d15958e3340 class=n-a></a>Kodera Y, Ito S, Mochizuki Y, <i> et al.</i>: Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. <i>Gastric Cancer.</i> 2012; <b>15</b>(3): 335–7. <a target=xrefwindow id=d15958e3351 href="http://www.ncbi.nlm.nih.gov/pubmed/22527184">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3354 href="http://dx.doi.org/10.1007/s10120-012-0156-3">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d15958e3364 class=n-a></a>Kodera Y, Takahashi N, Yoshikawa T, <i> et al.</i>: Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. <i>Gastric Cancer.</i> 2017; <b>20</b>(1): 190–9. <a target=xrefwindow id=d15958e3375 href="http://www.ncbi.nlm.nih.gov/pubmed/26879545">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3378 href="http://dx.doi.org/10.1007/s10120-016-0598-0">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d15958e3387 class=n-a></a>Aizawa M, Ishigami H, Yabusaki H, <i> et al.</i>: Phase II study of intraperitoneal paclitaxel plus S-1/paclitaxel for gastric cancer with positive peritoneal cytology: CY-PHOENIX trial. <i>J Clin Oncol.</i> 2017; <b>35</b>(4_suppl): 96. <a target=xrefwindow id=d15958e3398 href="http://dx.doi.org/10.1200/JCO.2017.35.4_suppl.96">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d15958e3407 class=n-a></a>Badgwell B, Blum M, Das P, <i> et al.</i>: Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. <i>Ann Surg Oncol.</i> 2017; <b>24</b>(11): 3338–44. <a target=xrefwindow id=d15958e3418 href="http://www.ncbi.nlm.nih.gov/pubmed/28799004">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3421 href="http://dx.doi.org/10.1245/s10434-017-6047-4">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d15958e3430 class=n-a></a>Bartley AN, Washington MK, Colasacco C, <i> et al.</i>: <i>HER2</i> Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. <i>J Clin Oncol.</i> 2017; <b>35</b>(4): 446–64. <a target=xrefwindow id=d15958e3444 href="http://www.ncbi.nlm.nih.gov/pubmed/28129524">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3448 href="http://dx.doi.org/10.1200/JCO.2016.69.4836">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d15958e3457 class=n-a></a>Thuss-Patience PC, Shah MA, Ohtsu A, <i> et al.</i>: Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncol.</i> 2017; <b>18</b>(5): 640–53. <a target=xrefwindow id=d15958e3468 href="http://www.ncbi.nlm.nih.gov/pubmed/28343975">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3471 href="http://dx.doi.org/10.1016/S1470-2045(17)30111-0">Publisher Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725979900"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e3480 class=n-a></a>Hecht JR, Bang YJ, Qin SK, <i> et al.</i>: Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. <i>J Clin Oncol.</i> 2016; <b>34</b>(5): 443–51. <a target=xrefwindow id=d15958e3491 href="http://www.ncbi.nlm.nih.gov/pubmed/26628478">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3494 href="http://dx.doi.org/10.1200/JCO.2015.62.6598">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725979900">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d15958e3508 class=n-a></a>Satoh T, Xu RH, Chung HC, <i> et al.</i>: Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of <i>HER2</i>-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. <i>J Clin Oncol.</i> 2014; <b>32</b>(19): 2039–49. <a target=xrefwindow id=d15958e3522 href="http://www.ncbi.nlm.nih.gov/pubmed/24868024">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3526 href="http://dx.doi.org/10.1200/JCO.2013.53.6136">Publisher Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718006635"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e3535 class=n-a></a>Lordick F, Kang YK, Chung HC, <i> et al.</i>: Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(6): 490–9. <a target=xrefwindow id=d15958e3546 href="http://www.ncbi.nlm.nih.gov/pubmed/23594786">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3549 href="http://dx.doi.org/10.1016/S1470-2045(13)70102-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718006635">F1000 Recommendation</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718006634"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e3562 class=n-a></a>Waddell T, Chau I, Cunningham D, <i> et al.</i>: Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(6): 481–9. <a target=xrefwindow id=d15958e3573 href="http://www.ncbi.nlm.nih.gov/pubmed/23594787">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3576 href="http://dx.doi.org/10.1016/S1470-2045(13)70096-2">Publisher Full Text </a> | <a target=xrefwindow id=d15958e3580 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3669518">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718006634">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d15958e3593 class=n-a></a>Fuchs CS, Shitara K, Bartolomeo MD, <i> et al.</i>: RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma. <i>J Clin Oncol.</i> 2018; <b>36</b>(4_suppll): 5. <a target=xrefwindow id=d15958e3604 href="http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.5">Reference Source</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d15958e3613 class=n-a></a>Ohtsu A, Shah MA, Van Cutsem E, <i> et al.</i>: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. <i>J Clin Oncol.</i> 2011; <b>29</b>(30): 3968–76. <a target=xrefwindow id=d15958e3624 href="http://www.ncbi.nlm.nih.gov/pubmed/21844504">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3627 href="http://dx.doi.org/10.1200/JCO.2011.36.2236">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d15958e3636 class=n-a></a>Catenacci DVT, Tebbutt NC, Davidenko I, <i> et al.</i>: Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(11): 1467–82. <a target=xrefwindow id=d15958e3647 href="http://www.ncbi.nlm.nih.gov/pubmed/28958504">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3650 href="http://dx.doi.org/10.1016/S1470-2045(17)30566-1">Publisher Full Text </a> | <a target=xrefwindow id=d15958e3654 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5898242">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d15958e3664 class=n-a></a>Shah MA, Bang YJ, Lordick F, <i> et al.</i>: Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. <i>JAMA Oncol.</i> 2017; <b>3</b>(5): 620–7. <a target=xrefwindow id=d15958e3675 href="http://www.ncbi.nlm.nih.gov/pubmed/27918764">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3678 href="http://dx.doi.org/10.1001/jamaoncol.2016.5580">Publisher Full Text </a> | <a target=xrefwindow id=d15958e3682 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5824210">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d15958e3691 class=n-a></a>Ohtsu A, Ajani JA, Bai YX, <i> et al.</i>: Everolimus for previously treated advanced gastric cancer: Results of the randomized, double-blind, phase III GRANITE-1 study. <i>J Clin Oncol.</i> 2013; <b>31</b>(31): 3935–43. <a target=xrefwindow id=d15958e3702 href="http://www.ncbi.nlm.nih.gov/pubmed/24043745">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3705 href="http://dx.doi.org/10.1200/JCO.2012.48.3552">Publisher Full Text </a> | <a target=xrefwindow id=d15958e3709 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5950503">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d15958e3718 class=n-a></a>Al-Batran SE, Riera-Knorrenschild J, Pauligk C, <i> et al.</i>: A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). <i>J Clin Oncol.</i> 2017; <b>35</b>(4_suppl): 4. <a target=xrefwindow id=d15958e3729 href="http://dx.doi.org/10.1200/JCO.2017.35.4_suppl.4">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d15958e3738 class=n-a></a>Van Cutsem E, Bang YJ, Mansoor W, <i> et al.</i>: A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification. <i>Ann Oncol.</i> 2017; <b>28</b>(6): 1316–24. <a target=xrefwindow id=d15958e3749 href="http://www.ncbi.nlm.nih.gov/pubmed/29177434">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3752 href="http://dx.doi.org/10.1093/annonc/mdx107">Publisher Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1025649"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e3761 class=n-a></a>Farmer H, McCabe N, Lord CJ, <i> et al.</i>: Targeting the DNA repair defect in <i>BRCA</i> mutant cells as a therapeutic strategy. <i>Nature.</i> 2005; <b>434</b>(7035): 917–21. <a target=xrefwindow id=d15958e3775 href="http://www.ncbi.nlm.nih.gov/pubmed/15829967">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3779 href="http://dx.doi.org/10.1038/nature03445">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1025649">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d15958e3792 class=n-a></a>Bang YJ, Im SA, Lee KW, <i> et al.</i>: Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. <i>J Clin Oncol.</i> 2015; <b>33</b>(33): 3858–65. <a target=xrefwindow id=d15958e3803 href="http://www.ncbi.nlm.nih.gov/pubmed/26282658">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3806 href="http://dx.doi.org/10.1200/JCO.2014.60.0320">Publisher Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d15958e3816 class=n-a></a>Bang YJ, Xu RH, Chin K, <i> et al.</i>: Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): A double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(12): 1637–51. <a target=xrefwindow id=d15958e3827 href="http://www.ncbi.nlm.nih.gov/pubmed/29103871">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3830 href="http://dx.doi.org/10.1016/S1470-2045(17)30682-4">Publisher Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d15958e3839 class=n-a></a>Bekaii-Saab T, El-Rayes B: Identifying and targeting cancer stem cells in the treatment of gastric cancer. <i>Cancer.</i> 2017; <b>123</b>(8): 1303–12. <a target=xrefwindow id=d15958e3847 href="http://www.ncbi.nlm.nih.gov/pubmed/28117883">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3850 href="http://dx.doi.org/10.1002/cncr.30538">Publisher Full Text </a> | <a target=xrefwindow id=d15958e3853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5412889">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d15958e3862 class=n-a></a>Cohen DJ, Christos PJ, Kindler HL, <i> et al.</i>: Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. <i>J Clin Oncol.</i> 2013; <b>31</b>(15_suppl): 4011. <a target=xrefwindow id=d15958e3873 href="http://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.4011">Reference Source</a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d15958e3882 class=n-a></a>Sonbol MB, Bekaii-Saab T: A clinical trial protocol paper discussing the BRIGHTER study. <i>Future Oncol.</i> 2018; <b>14</b>(10): 901–6. <a target=xrefwindow id=d15958e3890 href="http://www.ncbi.nlm.nih.gov/pubmed/29297698">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3893 href="http://dx.doi.org/10.2217/fon-2017-0406">Publisher Full Text </a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d15958e3902 class=n-a></a>Yoon C, Park DJ, Schmidt B, <i> et al.</i>: CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. <i>Clin Cancer Res.</i> 2014; <b>20</b>(15): 3974–88. <a target=xrefwindow id=d15958e3913 href="http://www.ncbi.nlm.nih.gov/pubmed/24947926">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3916 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-0011">Publisher Full Text </a> | <a target=xrefwindow id=d15958e3920 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4135312">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d15958e3929 class=n-a></a>Sahin U, Koslowski M, Dhaene K, <i> et al.</i>: Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. <i>Clin Cancer Res.</i> 2008; <b>14</b>(23): 7624–34. <a target=xrefwindow id=d15958e3940 href="http://www.ncbi.nlm.nih.gov/pubmed/19047087">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3943 href="http://dx.doi.org/10.1158/1078-0432.CCR-08-1547">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d15958e3953 class=n-a></a>Al-Batran SE, Schuler MH, Zvirbule Z, <i> et al.</i>: FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. <i>J Clin Oncol.</i> 2016; <b>34</b>(18_suppl): LBA4001–LBA. <a target=xrefwindow id=d15958e3964 href="http://dx.doi.org/10.1200/JCO.2016.34.18_suppl.LBA4001">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733101542"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e3973 class=n-a></a>Shah MA, Starodub A, Sharma S, <i> et al.</i>: Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study. <i>Clin Cancer Res.</i> 2018; <b>24</b>(16): 3829–3837. <a target=xrefwindow id=d15958e3984 href="http://www.ncbi.nlm.nih.gov/pubmed/29691300">PubMed Abstract </a> | <a target=xrefwindow id=d15958e3987 href="http://dx.doi.org/10.1158/1078-0432.CCR-17-2469">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733101542">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d15958e4000 class=n-a></a>Bendell JC, Starodub A, Wainberg ZA, <i> et al.</i>: A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma. <i>J Clin Oncol.</i> 2016; <b>34</b>(15_suppl): TPS4132–TPS. <a target=xrefwindow id=d15958e4011 href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS4139">Reference Source</a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d15958e4020 class=n-a></a>Luke JJ, Flaherty KT, Ribas A, <i> et al.</i>: Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nat Rev Clin Oncol.</i> 2017; <b>14</b>(18): 463–82. <a target=xrefwindow id=d15958e4031 href="http://www.ncbi.nlm.nih.gov/pubmed/28374786">PubMed Abstract </a> | <a target=xrefwindow id=d15958e4034 href="http://dx.doi.org/10.1038/nrclinonc.2017.43">Publisher Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d15958e4043 class=n-a></a>Giroux Leprieur E, Dumenil C, Julie C, <i> et al.</i>: Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. <i>Eur J Cancer.</i> 2017; <b>78</b>: 16–23. <a target=xrefwindow id=d15958e4054 href="http://www.ncbi.nlm.nih.gov/pubmed/28407528">PubMed Abstract </a> | <a target=xrefwindow id=d15958e4057 href="http://dx.doi.org/10.1016/j.ejca.2016.12.041">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731932173"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e4066 class=n-a></a>Kang YK, Boku N, Satoh T, <i> et al.</i>: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2017; <b>390</b>(10111): 2461–71. <a target=xrefwindow id=d15958e4077 href="http://www.ncbi.nlm.nih.gov/pubmed/28993052">PubMed Abstract </a> | <a target=xrefwindow id=d15958e4080 href="http://dx.doi.org/10.1016/S0140-6736(17)31827-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731932173">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d15958e4094 class=n-a></a>Janjigian YY, Ott PA, Calvo E, <i> et al.</i>: Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study. <i>J Clin Oncol.</i> 2017; <b>35</b>(15_suppl): 4014. <a target=xrefwindow id=d15958e4105 href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4014">Reference Source</a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732851580"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e4114 class=n-a></a>Fuchs CS, Doi T, Jang RW, <i> et al.</i>: Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. <i>JAMA Oncol.</i> 2018; <b>4</b>(5): e180013. <a target=xrefwindow id=d15958e4125 href="http://www.ncbi.nlm.nih.gov/pubmed/29543932">PubMed Abstract </a> | <a target=xrefwindow id=d15958e4128 href="http://dx.doi.org/10.1001/jamaoncol.2018.0013">Publisher Full Text </a> | <a target=xrefwindow id=d15958e4132 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5885175">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732851580">F1000 Recommendation</a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d15958e4145 class=n-a></a>Bang YJ, Muro K, Fuchs CS, <i> et al.</i>: KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer. <i>J Clin Oncol.</i> 2017; <b>35</b>(15_suppl): 4012. <a target=xrefwindow id=d15958e4156 href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.4012">Reference Source</a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d15958e4165 class=n-a></a>Tabernero J, Bang YJ, Fuchs CS, <i> et al.</i>: KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. <i>J Clin Oncol.</i> 2016; <b>34</b>(4_suppl): TPS185–TPS. <a target=xrefwindow id=d15958e4176 href="http://dx.doi.org/10.1200/jco.2016.34.4_suppl.tps185">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d15958e4185 class=n-a></a>Chung HC, Arkenau HT, Wyrwicz L, <i> et al.</i>: Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. <i>J Clin Oncol.</i> 2016; <b>34</b>(15_suppl): 4009. <a target=xrefwindow id=d15958e4196 href="http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.4009">Reference Source</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727697784"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e4205 class=n-a></a>Le DT, Durham JN, Smith KN, <i> et al.</i>: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science.</i> 2017; <b>357</b>(6349): 409–13. <a target=xrefwindow id=d15958e4216 href="http://www.ncbi.nlm.nih.gov/pubmed/28596308">PubMed Abstract </a> | <a target=xrefwindow id=d15958e4219 href="http://dx.doi.org/10.1126/science.aan6733">Publisher Full Text </a> | <a target=xrefwindow id=d15958e4223 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5576142">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727697784">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727438624"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d15958e4237 class=n-a></a>Dempke WCM, Fenchel K, Uciechowski P, <i> et al.</i>: Second- and third-generation drugs for immuno-oncology treatment-The more the better? <i>Eur J Cancer.</i> 2017; <b>74</b>: 55–72. <a target=xrefwindow id=d15958e4248 href="http://www.ncbi.nlm.nih.gov/pubmed/28335888">PubMed Abstract </a> | <a target=xrefwindow id=d15958e4251 href="http://dx.doi.org/10.1016/j.ejca.2017.01.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727438624">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1365&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1365&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA<br/> <sup>2</sup> Department of Gastroenterological Surgery, Graduate School of Medical Science, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan<br/> <sup>3</sup> Department of Gastroenterology and Hepatology and Inserm U954, Nancy University Hospital, Lorraine University, 5 all&eacute;e du Morvan, 54511 Vandoeuvre-l&egrave;s-Nancy, France<br/> <sup>4</sup> Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA<br/> <p> <div class=margin-bottom> Kazuto Harada <br/> <span>Roles: </span> Conceptualization, Data Curation, Formal Analysis, Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Anthony Lopez <br/> <span>Roles: </span> Conceptualization, Data Curation, Investigation, Writing – Original Draft Preparation </div> <div class=margin-bottom> Namita Shanbhag <br/> <span>Roles: </span> Conceptualization </div> <div class=margin-bottom> Brian Badgwell <br/> <span>Roles: </span> Conceptualization </div> <div class=margin-bottom> Hideo Baba <br/> <span>Roles: </span> Conceptualization, Supervision </div> <div class=margin-bottom> Jaffer Ajani <br/> <span>Roles: </span> Conceptualization, Funding Acquisition, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-1365/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Aug 2018, 7:1365 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.15133.1">https://doi.org/10.12688/f1000research.15133.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Harada K <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=16487 data-id=15133 data-downloads="" data-views="" data-scholar="10.12688/f1000research.15133.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-1365/v1/pdf?article_uuid=7b18fc0c-d803-441a-a98b-232f0bb38fdc" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.15133.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Harada K, Lopez A, Shanbhag N <em>et al.</em> Recent advances in the management of gastric adenocarcinoma patients [version 1; peer review: 2 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):1365 (<a href="https://doi.org/10.12688/f1000research.15133.1" target=_blank>https://doi.org/10.12688/f1000research.15133.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=15133 id=mobile-track-article-signin-15133 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/15133?target=/articles/7-1365"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=16487 /> <input name=articleId type=hidden value=15133 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Rebecca KS Wong</strong>, Princess Margaret Cancer Center, Dept Radiation Oncology, University of Toronto, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Rupert Langer</strong>, University of Bern, Institute of Pathology, Switzerland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Aug 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-1365&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-1365&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=38153-37409></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=22146-37410></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-1365/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Aug 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Rebecca KS Wong</strong>, Princess Margaret Cancer Center, Dept Radiation Oncology, University of Toronto, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Rupert Langer</strong>, University of Bern, Institute of Pathology, Switzerland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-1365&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-1365/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the management of gastric...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-1365/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-1365/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-1365/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Harada K et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-1365/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-1365",
            templates : {
                twitter : "Recent advances in the management of gastric adenocarcinoma patients. Harada K et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-1365/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the management of gastric adenocarcinoma patients", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the management of gastric adenocarcinoma patients", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/15133/16487")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "16487");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "37409": 0,
                           "37410": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "a3101129-5d04-498e-abe6-8cdbb683159f";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1365.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1365.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-1365.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-1365.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-1365.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>